Clinical trial • Phase IV • Neurology

CLOZAPINE for Schizophrenia

Phase IV trial of CLOZAPINE for Schizophrenia. 200 participants.

Overview

Trial Therapeutic Area
Neurology
Trial Disease
Schizophrenia
Trial Stage
Phase IV
Drug Modality
Small molecule

Key dates

Initial CTIS Submission Date
10-10-2024
First CTIS Authorization Date
23-10-2024

Trial design

Phase IV trial across 1 site in Denmark.

Target Sample Size
200

Eligibility

Recruits 200 No vulnerable population selected. Inclusion criterion requires participants to be "Legally competent". Informed consent documents for adults are provided (documents titled 'L1_SIS and ICF - adults -Informed consent' and 'L1_SIS and ICF - adults -Subject information'). No assent process for minors is described..

Pregnancy Exclusion
Pregnancy (will be verified by urine-HCG-test in fertile females)
Vulnerable Population
No vulnerable population selected. Inclusion criterion requires participants to be "Legally competent". Informed consent documents for adults are provided (documents titled 'L1_SIS and ICF - adults -Informed consent' and 'L1_SIS and ICF - adults -Subject information'). No assent process for minors is described.

Inclusion criteria

  • {"criterion_text":"- According to ICD-10 fulfill diagnostic criteria of schizophrenia (F20.x), chronical paranoid psychoses (F22), Schizoaffective psychoses (F25) or other non-organic psychoses (F28/29)\n- Age 18-64 years\n- Legally competent\n- Stable antipsychotic treatment during the last month\n- Being treatment refractory according to TRIPP-guidelines (Howes et al. 2017) defined as having tried at least two antipsychotic drugs in sufficient dosage (≥600 mg clorpromazine equivalent) for a sufficient time (≥ 6 weeks) without sufficient symptom improvement (still a moderate level of positive symptoms).\n- Recreational use of substances is allowed as long as it does not interfere with compliance\n- Fertile females must use safe contraception (spiral or any hormonal contraception)."}

Exclusion criteria

  • {"criterion_text":"- Involuntarily psychiatric admittance during the study\n- Substance abuse that interfere with compliance\n- Any condition that interfere with compliance for obtaining bloodsamples weekly\n- Pregnancy (will be verified by urine-HCG-test in fertile females)\n- Females who are breastfeeding\n- Toxic or idiosyncratic agranulocytosis in the past\n- Reduced bone marrow function according to blood samples (normal function defined as leucocytes > 3.3*109/l and neutrophil > 2.0*109/l)\n- According to information from patient and available files, no o\tCurrent uncontrolled epilepsy o\tCurrent circulatory collapse and / or CNS depression for any cause o\tCurrent severe kidney, heart or liver disease o\tCurrent paralytic ileus"}

Endpoints

Primary endpoints

  • {"endpoint_text":"- Permeability of the blood-brain barrier blood and CSF inflammatory cytokines","definition_or_measurement_approach":""}

Recruitment

Planned Sample Size
200
Recruitment Window Months
120
Consent Approach
Informed consent is obtained from legally competent adults. Documents provided include 'L1_SIS and ICF - adults -Informed consent' and 'L1_SIS and ICF - adults -Subject information'. No procedures for assent or parental consent for minors are described.

Geography

Total Number Of Sites
1
Total Number Of Participants
200

Denmark

Earliest CTIS Part Ii Submission Date
17-10-2024
Latest Decision Or Authorization Date
23-10-2024
Processing Time Days
6
Number Of Sites
1
Number Of Participants
200

Sites

Site Name
Region Hovedstadens Psykiatriske
Department Name
Enhed for kompliceret skizofreni
Contact Person Name
Jimmi Nielsen
Contact Person Email
jimmi.nielsen@regionh.dk

Sponsor

Primary sponsor

Full Name
Region Hovedstaden
Organisation Type
Hospital/Clinic/Other health care facility
Country Of Registered Address
Denmark

Third parties

  • {"country":"Denmark","full_name":"Frederiksberg Hospital","duties_or_roles":"1","organisation_type":"Hospital/Clinic/Other health care facility"}

Investigational products

Investigational Product Name
CLOZAPINE
Active Substance
CLOZAPINE
Modality
Small molecule
Routes Of Administration
ORAL USE
Route
ORAL USE
Authorisation Status
Authorised and marketed
Maximum Dose
900 mg

Related trials

Other published trials that may interest you.